Key clinical point: Modified Glasgow prognostic score (mGPS) predicts sarcopenia and is a strong prognostic factor for overall survival in patients with advanced gastric cancer or esophagogastric junction cancer undergoing first-line treatment.
Major finding: Baseline mGPS was significantly correlated with baseline mean muscle attenuation ( P < .0001). The mGPS was a strong prognostic factor for overall survival ( P < .0001) and progression-free survival ( P < .001).
Study details: Computed tomography was performed in 509 patients with advanced gastric or esophagogastric junction cancer from the phase 3 EXPAND trial who received first-line platinum-fluoropyrimidine chemotherapy.
Disclosures: No funding source was identified for this study. The authors received personal fees and research grants outside this work.
Source: Hacker UT et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol. 2022 (Apr 4). Doi: 10.1016/j.annonc.2022.03.274